Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide
- 1 March 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 24 (Suppl 1) , S39-S43
- https://doi.org/10.1097/01.hjh.0000220405.38622.23
Abstract
The important role of the endothelium for regulation of vascular tone, growth, inflammatory response, coagulation and thrombocyte adhesion has now been recognized. Endothelial function has largely been assessed as endothelium-dependent vasodilation, assuming that endothelium-dependent vasomotion represents a surrogate marker for other important endothelial functions. An important rational for this approach has been the observation that both endothelium-dependent vasomotion and other protective endothelial functions are at least partially mediated by nitric oxide. Accumulating clinical studies have now demonstrated a close and independent association of impaired endothelium-dependent vasodilation with cardiovascular events and prognosis. These findings have stimulated interest in treatment options to improve endothelial function in patients at high cardiovascular risk.This article describes recent insights into endothelial effects of both angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 (AT1) receptor blockade, which have both been shown to improve endothelial function (i.e. by increasing endothelial nitric oxide availability via bradykinin-dependent endothelial nitric oxide release). ACE has a high affinity for bradykinin and degrades the peptide, so ACE inhibition may increase bradykinin-dependent effects by preventing bradykinin degradation. Interestingly, AT1-receptor blockade appears to stimulate the bradykinin-nitric oxide pathway by increased angiotensin II type 2 receptor activation. Moreover, both treatment strategies prevent increased inactivation of endothelial nitric oxide by oxygen radicals, by reducing AT1-receptor-dependent activation of the oxidant enzyme NADPH oxidase and increasing the activity of the vascular antioxidant enzyme extracellular superoxide dismutase. These beneficial effects of ACE inhibition and AT1-receptor blockade are likely to contribute to their effects on cardiovascular events.Keywords
This publication has 37 references indexed in Scilit:
- Cardiovascular and Renal Regulation by the Angiotensin Type 2 ReceptorHypertension, 2005
- Losartan Increases Bradykinin Levels in Hypertensive HumansCirculation, 2005
- Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or deathEuropean Heart Journal, 2004
- Flow-Dependent Dilation Mediated by Endogenous Kinins Requires Angiotensin AT 2 ReceptorsCirculation Research, 2004
- AT 1 -Receptor Antagonism Improves Endothelial Function in Coronary Artery Disease by a Bradykinin/B 2 -Receptor-Dependent MechanismHypertension, 2003
- Mechanism of Endothelial Cell NADPH Oxidase Activation by Angiotensin IIJournal of Biological Chemistry, 2003
- Activation of AT 2 Receptors by Endogenous Angiotensin II Is Involved in Flow-Induced Dilation in Rat Resistance ArteriesHypertension, 1999
- Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilationJournal of Clinical Investigation, 1999
- Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.Journal of Clinical Investigation, 1996
- Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.Journal of Clinical Investigation, 1995